AtaiBeckley announced the appointment of Michael Faerm as Chief Financial Officer, effective March 9, 2026. As Chief Financial Officer at AtaiBeckley, he will lead the Company’s financial strategy, capital markets activities, and overall financial operations. Anne Johnson, who has served as Chief Financial Officer since 2024, will transition to the role of Chief Accounting Officer upon the effective date of Faerm’s appointment. Faerm most recently served as Chief Financial Officer at Viracta Therapeutics
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATAI:
- Psychedelic: Analyst initiates Atai Beckley with Buy rating
- Atai Beckley initiated with a Buy at Guggenheim
- ATAI Life Sciences: Advancing Psychedelic Pipeline Sets Up Data-Rich 2026 and Supports Reiterated Buy Rating
- Atai Beckley announces presentations at ACNP
- Advancing Neuropsychiatric Pipeline and Clear 2026 Milestones Underpin Buy Rating on ATAI Life Sciences
